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Abstract NADPH oxidase family enzymes (or NOXs)
are the major sources of reactive oxygen species (ROS)
that are implicated in the pathophysiology of many
cardiovascular diseases. These enzymes appear to be
especially important in the modulation of redox-sensitive
signalling pathways that underlie key cellular functions
such as growth, differentiation, migration and prolifera-
tion. Seven distinct members of the family have been
identiﬁed of which four (namely NOX1, 2, 4 and 5) may
have cardiovascular functions. In this article, we review
our current understanding of the roles of NOX enzymes
in several common cardiovascular disease states, with a
focus on data from genetic studies and clinical data
where available.
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Introduction
Reactive oxygen species (ROS) have long been known to
be capable of inducing detrimental effects through the
oxidation and damage of cellular macromolecules,
membranes, proteins and DNA, when they overwhelm
endogenous antioxidant defences—a condition known as
oxidative stress. More recently, however, it has been
appreciated that they also modulate speciﬁc cellular sig-
nalling pathways through targeted effects on susceptible
molecules, especially when generated in lower amounts—
an action that is termed ‘‘redox signalling’’ [25, 56]. Redox
signalling and oxidative stress are important in numerous
cardiovascular conditions such as atherosclerosis, hyper-
tension and heart failure [28, 30, 72, 85].
Potential sources of cellular ROS include mitochon-
dria, NADPH oxidase family enzymes (or NOXs), dys-
functional nitric oxide (NO) synthases, xanthine oxidase
and other oxygenases. Among these sources, the NOXs
are unique in that ROS production is their primary
function rather than a secondary effect [7]. Furthermore,
they appear to be especially important in the modulation
of redox-sensitive signalling pathways that underlie key
cellular functions such as growth, differentiation,
migration and proliferation. A large body of work pub-
lished over the last decade indicates that NOX enzymes
play important roles in the pathophysiology of many
cardiovascular diseases [12, 16, 69]. Over this period,
much has been learnt about the complexity of these
enzymes, their regulation and their involvement in spe-
ciﬁc pathological processes. The most compelling data
derive from studies that have used gene-modiﬁed animal
models or speciﬁc genetic approaches to deﬁne the
functions of these enzymes since chemical inhibitors of
the enzymes lack speciﬁcity [2, 47]. Here, we provide a
brief review of the current understanding of the roles of
NOX enzymes in several common cardiovascular disease
states, with a focus on data from genetic studies. We
also review clinical data supporting a role for NOXs,
where available.
A. Sirker  M. Zhang  A. M. Shah
Cardiovascular Division, King’s College London British Heart
Foundation Centre, London SE5 9PJ, UK
A. M. Shah (&)
Cardiovascular Division, The James Black Centre, King’s
College London, 125 Coldharbour Lane, London SE5 9NU, UK
e-mail: ajay.shah@kcl.ac.uk
123
Basic Res Cardiol (2011) 106:735–747
DOI 10.1007/s00395-011-0190-zNADPH oxidase structure and regulation
The NOX family oxidases comprise seven members, each
based on a distinct core catalytic subunit; i.e. NOX1–5 and
DUOX1–2 [7, 66]. All NOX enzymes utilize NADPH as an
electrondonorandcatalysetransferofelectronstomolecular
oxygen to generate superoxide (O2
-) and/or hydrogen per-
oxide (H2O2). NOX 1, 2, 4 and 5 may be expressed in car-
diovascular cells although NOX5 is only found in humans
and not rodents. The enzymes have differing requirements
for other subunits and also exhibit differences in activity
(Fig. 1;Table 1).NOX1,2and4allbindtoasmallerp22
phox
subunit, which is essential for enzyme activity. NOX1 and 2
are normally activated after cell stimulation by speciﬁc
agonists (e.g. G-protein coupled receptor agonists such as
angiotensin II, growth factors, cytokines and mechanical
forces), which induce the association of regulatory subunits
and activation of the enzyme. In the case of NOX2, the
cytosolic regulatory subunits are p47
phox, p67
phox, p40
phox
and Rac1 whereas NOX1 binds to the analogues of p47
phox
and p67
phox termed NOXO1 and NOXA1, respectively, as
well as Rac1. In marked contrast, NOX4 is constitutively
active and does not require association with regulatory
subunits,withregulationthoughttooccurmainlybychanges
in expression level. Furthermore, recent ﬁndings from sev-
eral laboratories intriguingly suggest that NOX4 predomi-
nantly generates H2O2 in contrast to NOX1 and 2, which
generate O2
- [21, 83, 103]. The biochemical basis for this
property of NOX4 has recently been suggested to be related
to the structure of its third extracytosolic loop, which differs
signiﬁcantly from those of NOX1 or 2 and contains a highly
conserved histidine moiety which may prevent superoxide
release or may provide protons for superoxide dismutation
[108]. NOX5 is regulated by calcium binding as a conse-
quence of EF motifs in its N-terminal domain.
NOX1 is expressed mainly in vascular smooth muscle
cells (VSMC) although endothelial cell expression has also
been reported. NOX2 (also known as gp91
phox oxidase) was
the ﬁrst NADPH oxidase to be identiﬁed, being responsible
for the phagocytic oxidative burst of neutrophils. Its neu-
trophil activity is important for non-speciﬁc host defence
against microbial organisms and deﬁcient activity of the
oxidase results in chronic granulomatous disease (CGD), a
condition in which affected children develop recurrent
infections and inﬂammation. NOX2 has subsequently been
found to be expressed at lower level in other inﬂammatory
cells as well as in endothelial cells, cardiomyocytes, ﬁbro-
blasts and VSMC. NOX4 is reported to be expressed in all
cardiovascular cell types although its in vivo level of
expression in healthy cardiovascular tissues remains to be
precisely deﬁned. NOX5 is reportedly expressed in human
endothelial cells and VSMC althoughthe data supporting its
involvement in cardiovascular pathology are much weaker
than that for the other NOX isoforms.
Hypertension
NOXs are expressed in all layers of the vessel wall as well
as in other key organs, such as the kidney and the central
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Fig. 1 Schematic
representation of NOX1, NOX2,
NOX4 and NOX5 oxidases.
NOX1 and NOX2 require
association with cytosolic
regulatory subunits for their
activation, as indicated
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123nervous system (CNS), that affect the regulation of blood
pressure (BP) [7, 52, 68, 94].
At the level of the vessel wall, ROS may affect vascular
resistance either by direct modulation of vessel tone or by
affecting vascular remodelling [92]. Vascular O2
- pro-
duction can disrupt physiological NO signalling through its
inactivation and the production of peroxynitrite, resulting
in a net vasoconstrictor effect. However, H2O2 has vaso-
dilator actions through several mechanisms and could
potentially reduce vessel tone. NOX-modulated alterations
in activation of redox-sensitive signalling pathways that are
involved in the vascular remodelling characteristic of
chronic hypertension are also important [10]. Recently,
evidence was reported that NOX2 activation in inﬂamma-
tory cells (in particular, T-cells) that inﬁltrate the vessel
wall is important in angiotensin II-dependent hypertension
[43].
At renal level, ROS-modulated mechanisms have been
shown to operate downstream of major determinants of
blood pressure, namely hormonal regulation and sodium
balance. Angiotensin II-mediated experimental hyperten-
sion is associated with oxidative stress [97] and amelio-
rated by treatment with superoxide dismutase [71].
Angiotensin II infusion is associated with an upregulation
of NADPH oxidase activity in the renal cortex in rat and
rabbit models [17, 78, 116, 117], with upregulation of
NOX1 mRNA expression and downregulation of NOX4
mRNA expression [17]. In contrast, a high salt intake
suppresses the renin–angiotensin–aldosterone axis and yet
is also associated with an increase in NADPH oxidase
activity in the renal cortex, accompanied by upregulation
of gp91 (NOX2) and p47
phox mRNA [63]. A low salt intake
produces the opposite changes. Hence there is a distinct
pattern of activation of NADPH oxidase isoforms in the
kidney in response to these different stimuli which are of
known importance in the long-term control of blood
pressure.
Finally, at CNS level, ROS are involved in modulating
neuronal outputs that affect the central control of BP.
Angiotensin II in the circulation is detected by certain areas
of the brain outside the blood–brain barrier, including the
subfornical organ (SFO). Studies by the group of Davisson
showed that ROS appear to be responsible for mediating
key central actions of Angiotensin II, including effects on
blood pressure and thirst [125, 126]. Using adenoviral-
based inhibition or overexpression of Rac1, this group also
demonstrated that a Rac1-dependent NADPH oxidase
(presumably NOX2) is the critical source for this ROS
[124].
As suggested by the data presented above, the inﬂuence
of NOXs on blood pressure has been most extensively
studied in the models of angiotensin II-induced hyperten-
sion. In rodents, angiotensin II increases NOX-dependent
ROS production in vessels, kidneys and CNS [17, 19, 33,
67, 77, 97, 115, 125]. This is associated with increases in
NOX subunit expression and activity in all cell types
within the vessel wall. Studies using systemic infusion of
the peptide gp91-dstat (which inhibits activation of NOX2
and possibly other NOX isoforms) showed a signiﬁcant
attenuation of angiotensin II-induced hypertension and
superoxide production in mice [99]. Use of siRNA targeted
against p22
phox in rats was reported to reduce renal cortex
NOX1, 2 and 4 expression and overall renal NADPH
oxidase activity and to signiﬁcantly reduce the pressor
response to angiotensin II [87]. Additional data derive from
the studies in gene-modiﬁed mouse models. Mice with a
VSMC-speciﬁc overexpression of p22
phox did not develop
hypertension, although interpretation of the results was
potentially confounded by concurrent major changes in the
expression of antioxidant genes and NO synthase [70].
Mice lacking the organizer subunit p47
phox showed mark-
edly blunted pressor responses to angiotensin II [67]. This
effect could involve NOX1 or NOX2, both of which may
be affected by p47
phox deﬁciency. Indeed, mice with a
Table 1 The activity, regulation and expression of the main NOXs in the cardiovascular system
NOX1 NOX2 NOX4 NOX5
Constitutive
activity
Absent or very low Absent or very low High Low
Requirement
for p22
phox
Yes Yes Yes No
Essential
regulatory
subunits
NOXO1, NOXA1, Rac p67
phox, p47
phox, p40
phox, Rac None None
Control Post-translational
modiﬁcations of
regulatory subunits
Post-translational modiﬁcations of
regulatory subunits
Transcriptional. Can be
regulated by Poldip2
Calcium binding
Cell
expression
Vascular smooth
muscle, possibly
endothelial cells
Endothelial cells, cardiomyocytes,
ﬁbroblasts, human vascular smooth
muscle, inﬂammatory cells
Endothelial cells,
cardiomyocytes, ﬁbroblasts,
vascular smooth muscle cells
Human endothelium,
human vascular
smooth muscle
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123global knockout of NOX1 showed signiﬁcant attenuation
of pressor responses to angiotensin II infusion [22, 36, 84],
whereas mice overexpressing NOX1 in VSMC showed
exaggerated BP responses compared to wild-type mice [22,
84]. In contrast, mice with a global deﬁciency of NOX2
were reported to have an unaltered BP response to angio-
tensin II [116], suggesting that this isoform is less impor-
tant. Similarly, crossing a global NOX2 knockout with
mice that had chronic angiotensin II-dependent hyperten-
sion due to transgenic liver expression of human renin
failed to affect BP [111]. While NOX4 levels are known to
be increased in models of renin-angiotensin II-dependent
hypertension [119], its possible role in the genesis of the
hypertension has been unclear. Recent studies in a model
of endothelial-speciﬁc NOX4 overexpression showed that
NOX4 enhanced endothelium-dependent relaxation as a
result of H2O2-dependent vasodilatation [98], opposite to
the effects of NOX1 or NOX2. This effect involved H2O2-
dependent hyperpolarization rather than a change in NO
bioactivity. In addition to the enhanced vasodilatation,
NOX4 transgenic mice had a lower BP than wild-type
littermates and displayed a blunted hypertensive response
to angiotensin II infusion [98]. These data suggest that
elevation of NOX4 could act to counteract the hypertensive
effects of angiotensin II and thereby act in opposition to the
pro-hypertensive effects of NOX1 and NOX2 (Fig. 2).
The roles of NOX2 and NOX4 in the CNS have also
been investigated. Studies using adenoviral-mediated
knockdown of NOX2 or NOX4 in the subfornical organ in
the CNS reported that both isoforms are required for the
full pressor response to angiotensin II in the brain but that
only NOX2 was coupled to the water intake response [94].
Data on the possible involvement of NOXs in other forms
of experimental hypertension are largely restricted to cor-
relative data although it was reported that norepinephrine-
induced hypertension was unaffected in NOX1 knockout
mice, in contrast to angiotensin II-induced hypertension
[37].
In human studies, an association between ‘essential’ (i.e.
idiopathic) hypertension and increased vascular NOX
expression has been demonstrated in work using resistance
arteries from gluteal fat biopsies [112]. Patients with
hypertension have also been shown to have endothelial
dysfunction in saphenous veins that is attributable to
increased NOX-dependent ROS generation [44]. Human
genetic studies also revealed polymorphisms of p22
phox
which appear relevant to hypertension. The C242T,
-930(A/G) and -675(A/T) polymorphisms of CYBA, the
gene encoding for p22
phox, were reported to be associated
with increased phagocytic NADPH oxidase activity and
increased susceptibility to hypertension [88, 89, 121].
Atherosclerosis
There are several reasons to suspect an involvement of
NADPH oxidases in atherosclerosis. Besides being found
in all layers of the blood vessel wall [40, 44], the enzyme is
present in the macrophage, a central player in atherogen-
esis [20]. O2
- can oxidize LDL and atherogenic oxi-
dized LDL itself stimulates NADPH oxidase [3, 5, 100].
O2
--mediated inactivation of NO promotes endothelial
activation and VSMC proliferation, also important steps in
atherogenesis [35, 59]. In addition, NOX-modulated redox
ab
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Fig. 2 Contrasting vascular
effects of NOX1/2 versus
NOX4. a NOX1 and NOX2
promote endothelial dysfunction
and vascular remodelling, at
least in part through O2
--
dependent inactivation of NO.
NOX4 on the other hand
enhances endothelial-dependent
relaxation through H2O2-
dependent hyperpolarization.
These effects may contribute to
changes in BP. b Effects of
endothelial-speciﬁc NOX4
overexpression on ambulatory
BP measured by telemetry (top)
and acetylcholine (Ach)-induced
relaxation in isolated aortic
rings. Tg transgenic mice; SBP
systolic BP; DBP diastolic BP.
***P\0.001. Reproduced with
permission from [98]
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123signalling may accentuate both these processes. Interest-
ingly, the propensity of atherosclerotic lesions to form in
areas of turbulence such as arterial branch points might
also involve mechanical activation of NOXs [38].
Mice with global NOX2 deﬁciency that were crossed
with atherosclerosis-prone apoE
-/- mice and fed a high
fat diet were found to have no obvious protection against
atherosclerosis when examining aortic sinus sections [62].
Similar results were reported in global p47
phox knockout
mice crossed with ApoE
-/- mice [51]. In contrast, Barry-
Lane et al. [6] found that total aortic lesion area (from arch
to bifurcation) was reduced in p47
phox knockout mice
crossed with ApoE
-/-, suggesting that NOX1 and/or
NOX2 may be involved in atherogenesis. Very recently,
similar observations have been described in the NOX2/
ApoE double knockout mouse with a high-fat diet. [58].
Absence of NOX2 activity did not alter the disease burden
within the aortic sinus but was associated with a 50%
reduction in lesion area in the region between aortic arch
and (iliac) bifurcation. The relevant cellular source was not
delineated in these experiments but has been addressed in
other work. Khatri et al. [60] employed a ligation-induced
model of carotid atheroma in mice with transgenic VSMC-
speciﬁc overexpression of p22
phox. These animals showed
enhanced growth of arterial lesions associated with a
greater degree of expansive arterial remodelling, possibly a
consequence of increased matrix metalloproteinase (MMP)
activity. These lesions also showed enhanced angiogenesis
(discussed later). Equivalent studies using genetically
modiﬁed animals for the other vascular isoforms, NOX1
and NOX4, are not presently available.
Very recently, data implicating a role for NADPH oxi-
dase in macrophage trapping in the neointima of lesions
have become available. Oxidized LDL-induced changes in
macrophage function via CD36 signalling were found to
involve ROS-dependent inactivation of the phosphatase
SHP2 [93]. This was inhibited by DPI and apocynin, sug-
gesting that it may be NADPH oxidase-dependent although
clearly not deﬁnitive.
Other indirect evidence comes from the actions of the
renin inhibitor aliskiren which was found to reduce aortic
sinus plaque area in ApoE
-/- mice, seemingly independent
of its blood pressure lowering effects, whilst also reducing
vascular NOX activity [96]. In contrast, CB-1 cannabinoid
receptor inhibition did not reduce atherosclerosis in
ApoE
-/- mice but did improve aortic endothelial-depen-
dent vasodilation whilst reducing ROS production and
NOX activity [109].
In humans, the C242T polymorphism of the CYBA gene
(which encodes p22
phox) has been linked to increased risk
of coronary artery disease or progression of coronary artery
disease in certain subgroups with the T allele [14, 15],
although other authors have suggested a protective effect of
this allele [29, 55]. These disparate ﬁndings may relate, at
least in part, to differences in the populations under study
and the endpoints used.
Human pathological specimens have also been used for
the analysis of NADPH oxidase expression. Azumi et al.
[4] found increased immunostaining for p22
phox protein in
atherosclerotic coronary arteries compared to non-athero-
sclerotic arteries, and showed that this co-localized with
markers for endothelial cells, smooth muscle cells, inﬁl-
trating macrophages and adventitial ﬁbroblasts. Later work
by Sorescu and colleagues [106] supported these ﬁndings
and found that p22
phox co-localized with NOX2 predomi-
nantly in macrophages and particularly in the plaque
shoulder regions. mRNA levels for p22
phox and NOX2
correlated with lesion severity in this study. In contrast,
NOX4 staining was most marked in the vessel media and
correlated with VSMC cell density in atherosclerotic
lesions. Recently, attention has also focussed upon vascular
NOX5 [42, 102]. Guzik et al. studied human coronary
arteries from explanted heart tissue and reported that
NOX5 mRNA and protein levels were upregulated in
atherosclerotic arteries, with staining evident in both the
neointima and adjacent medial VSMC. NOX5 contributed
signiﬁcantly to overall NADPH oxidase-generated ROS in
these arteries. An unexpected ﬁnding from other recent
work is that NOX5 may directly activate eNOS, possibly
counteracting the effects of NOX’s primary product in
consuming NO [123].
Ischaemic neovascularization
A signiﬁcant body of data implicates ROS in the process of
angiogenesis and ischaemic neovascularisation, with in
vivo evidence suggesting an involvement of NOXs in this
process. Using an in vivo sponge implant model in which
topical injection of VEGF or sphingosine 1-phosphate
stimulated new vessel formation, Ushio-Fukai et al. [114]
found that NOX2 knockout mice had reduced VEGF-
induced new vessel formation. Later work used a hindlimb
ligation model and found that NOX2 knockout mice
developed reduced neovascularisation after ischaemia
[110]. The ischaemic regions of wild-type mice subjected
to hindlimb ischaemia demonstrated an increase in NOX2
protein expression and O2
- production, with NOX2
localized to inﬁltrating leucocytes acutely and then in
newly formed capillaries at a later stage [110]. Supportive
work comes from a retinal neovascularization model in
which ROS generation in the ischaemic retina was asso-
ciated with an increase in NOX2 levels and was reduced by
pre-treatment with gp91ds-tat [1].
Recent work investigated the possible contribution of
bone marrow-derived cells, using chimeric mice in which
Basic Res Cardiol (2011) 106:735–747 739
123either bone marrow cells and/or resident tissue cells lacked
NOX2 [113]. In the setting of hindlimb ischaemia, these
studies showed that bone marrow-derived cells were the
main source of NOX2 that was involved in post-ischaemic
neovascularisation. Ebrahimian and colleagues [27] also
studied bone marrow chimeric mice in a similar model but
this time with or without diabetes. These authors found that
NOX2 was required for post-ischaemic neovascularisation
in non-diabetic mice whereas NOX2 impaired neovascu-
larisation in diabetic mice. The authors proposed that the
effects of ROS on neovascularisation depended upon the
level of ROS that were generated, with high ROS levels in
the setting of diabetes being detrimental. The in vivo
effects of other NOX isoforms remain to be established
using speciﬁc genetic approaches.
Cardiac hypertrophy and ﬁbrosis
Myocardial hypertrophy occurs in response to chronic
stresses such as cardiac overload and involves both
mechanical and various neurohumoral stimuli (e.g. acti-
vation of the renin-angiotensin system, b-adrenergic acti-
vation, cytokines). NOX enzymes are found in multiple
cardiac cell types—namely cardiomyocytes, endothelial
cells, ﬁbroblasts and vascular smooth muscle cells—as
well as in inﬁltrating inﬂammatory cells. Furthermore,
NOX enzymes, particularly NOX1 and 2, are activated by
known pro-hypertrophic stimuli such as angiotensin II,
tumour necrosis factor a (TNFa) and mechanical stretch
[32, 53, 75, 76, 120]. It is, therefore, perhaps not unex-
pected that they are involved in mediating cardiac
hypertrophy.
Using a model of experimental cardiac hypertrophy
induced by chronic subpressor infusion of angiotensin II,
Bendall et al. [9] made the initial observation that NOX2
was critical for this response since hypertrophy was
markedly inhibited in NOX2 knockout mice. This was
accompanied by an inhibition of interstitial cardiac
ﬁbrosis in NOX2 knockout mice. Later studies provided
evidence that this effect on hypertrophy involved car-
diomyocyte NOX2. Satoh and colleagues [101] studied
mice with a cardiomyocyte-speciﬁc deletion of Rac1 and
found that these animals had markedly blunted hypertro-
phic responses to angiotensin II infusion. As discussed
above, Rac1 is required for NOX2 activation and these
authors showed the Rac1 deﬁcient mice also had deﬁcient
activation of NOX2 together with reduced activation of
ASK1 and NF-jB.
Early studies in experimental models of aortic con-
striction-induced pressure overload hypertrophy found a
progressive increase in left ventricular NOX-dependent
ROS generation which was associated with an increase in
expression of NOX2 and related oxidase subunits and was
accompanied by MAP kinase (MAPK) activation—sug-
gesting that these may be downstream targets of NOX-
generated ROS [74]. However, studies in NOX2 knockout
mice found that this subunit was not essential for the
development of hypertrophy. These animals developed a
similar degree of hypertrophy and similar increases in
molecular markers of hypertrophy as wild-type littermates
[13]. Similar results were obtained by an independent
group [86], indicating that there are signiﬁcant differences
between angiotensin II and pressure overload-induced
hypertrophy with respect to an essential requirement for
NOX2.
Despite the lack of requirement for NOX2 for the
development of pressure overload hypertrophy, it was
found that NOX2 knockout mice developed less intersti-
tial ﬁbrosis and contractile dysfunction than wild-type
littermates [41]—indicating a dissociation between
hypertrophy per se and ﬁbrosis or contractile dysfunction.
In line with this, NOX2 has been shown to be critical for
the development of interstitial cardiac ﬁbrosis in models
of high-dose angiotensin II infusion [57] or activation
[111] as well as in aldosterone/salt hypertension [57],
even though it had no effect on the extent of hypertrophy.
These results may indicate cell type-speciﬁc effects of
NOX2 in the development of cardiac hypertrophy and
ﬁbrosis.
In early studies of the role of NOX2 in pressure overload
hypertrophy, Byrne et al. [13] found that NADPH oxidase
activity increased to similar levels in NOX2 knockout and
wild-type mice, and that this was the result of an increase
in NOX4 levels. It was accordingly speculated that NOX4
might compensate for NOX2 in this setting. However, as
mentioned earlier, the two NOX isoforms differ signiﬁ-
cantly in terms of their regulation. In addition, whereas
activated NOX2 is located at the sarcolemma [49], NOX4
is found in an intracellular perinuclear location [122].
Recent studies from our laboratory have investigated the
role of NOX4 using newly generated mouse models with a
deletion of NOX4 or a cardiomyocyte-targeted increase in
NOX4 expression. Neither model developed signiﬁcant
basal changes in cardiac hypertrophy or function [122].
After imposition of chronic pressure overload, however,
NOX4 KO mice developed signiﬁcantly greater hypertro-
phy and contractile dysfunction than controls whereas
NOX4 transgenic mice exhibited protection against
hypertrophy and failure. The underlying mechanism was
found to be a NOX4-dependent preservation of myocardial
capillary density during pressure overload, which involved
an augmentation of stress-induced cardiomyocyte hypoxia-
inducible factor 1 (HIF1) activation and the release of
VEGF, resulting in increased paracrine angiogenic activity.
Whereas an insufﬁcient increase in capillary number
740 Basic Res Cardiol (2011) 106:735–747
123relative to increase in cardiomyocyte size during hyper-
trophy is thought to promote pathological remodelling of
the heart [104], the NOX4-dependent preservation of cap-
illary density may act to counteract this (Fig. 3). These
results on NOX4 along with the previous studies on NOX2
indicate that the two isoforms exert markedly different
effects during pressure overload-induced cardiac hyper-
trophy, with NOX2 being detrimental and NOX4
beneﬁcial.
Myocardial infarction, post-MI remodelling and heart
failure
Post-MI cardiac remodelling refers to structural and func-
tional alterations that occur in response to MI and predis-
pose to the development of heart failure [95]. Features of
post-MI cardiac remodelling include infarct expansion,
hypertrophy of non-infarcted myocardium, ventricular
dilatation, a change in chamber shape to a more spherical
geometry, and systolic and diastolic dysfunction. This is
associated with an increase in interstitial and perivascular
ﬁbrosis, other alterations in the extracellular matrix, and
cardiomyocyte hypertrophy and apoptosis [107].
Although some of the determinants of post-MI myo-
cardial remodelling, such as infarct size and neurohor-
monal status [18, 24, 45, 46], are the targets of currently
available therapies, there is still a need for new therapeutic
targets. Oxidative stress is implicated in the development
of post-MI remodelling and could, therefore, be a thera-
peutic target [48, 64]. Indeed, various antioxidant agents
have been shown to ameliorate remodelling after MI in
rodents [61, 90], while genetically modiﬁed mice with
increased activity of endogenous antioxidant systems were
also protected against post-MI ventricular dilatation and
dysfunction [105].
Speciﬁc involvement of NOX enzymes is suggested by
clinical data demonstrating an upregulation of NOX2 in
cardiomyocytes in patients who had died after MI [65]. An
increase in the expression of p22
phox and NOX2 proteins
has also been found in the infarcted region of rats after
experimental myocardial infarction [34]. More direct evi-
dence was derived from studies in genetically altered mice.
Early work showed that acute infarct size after in vivo
myocardial ischaemia/reperfusion was not signiﬁcantly
different between NOX2 knockout mice and wild type
[50]. However, studies by Bell and colleagues [8] reported
that NOX2 mediates ischaemic cardiac preconditioning in
isolated hearts, suggesting that it could affect infarct size
under some circumstances. Later studies have investigated
the role of NOX2 in post-MI remodelling. Looi and col-
leagues [81] studied NOX2 knockout mice subjected to
permanent left coronary ligation and found that post-MI
remodelling at 4 weeks was signiﬁcantly reduced despite
no difference in infarct size (Fig. 4). The improvement in
left ventricular volumes and function was accompanied by
a reduction in cardiomyocyte hypertrophy, apoptosis and
interstitial ﬁbrosis in the non-infarcted myocardium along
with a decrease in mRNA levels of connective tissue
growth factor (CTGF), procollagen I and ANF and lower
MMP activity. Strong support for such a role of NOX2
comes from independent studies that examined post-MI
remodelling in p47
phox knockout mice [23]. These animals
(which lack NOX2 activity) were also protected against
Nox4
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Fig. 3 Protective role of NOX4 during pressure overload cardiac
hypertrophy. a Representative images from NOX4 knockout mice or
wild-type littermates (WT) subjected to pressure overload by aortic
constriction. Panel A shows whole heart sections (scale bar 2 mm);
panel B shows myocardial sections stained with wheat-germ agglu-
tinin to show cardiomyocyte area; panel C shows myocardial sections
stained with Picrosirius Red to show ﬁbrosis (scale bars 20 lm).
NOX4 KO mice developed greater hypertrophy, ﬁbrosis and remod-
elling than WT after pressure overload. Reproduced with permission
from Zhang et al. [122]. b Schematic illustrating the mechanism
underlying protective effects of NOX4. Upregulation of NOX4
enhances HIF1 activation and the release of VEGF which exerts
paracrine effects to promote preservation of myocardial capillary
density
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123post-MI remodelling and dysfunction with a similar pattern
of underlying changes as found by Looi and colleagues. In
contrast to these studies, Frantz et al. [31] failed to ﬁnd a
similar beneﬁcial effect of NOX2 and instead reported a
higher mortality in NOX2 knockout mice. Some caveats to
this last study’s design are pertinent, e.g. the lack of lit-
termate controls which can be a confounding factor [39],
and the absence of a sham-operated group. Overall, NOX2
appears to play an important role in post-MI adverse car-
diac remodelling.
Very recently, NOXs within the central nervous system
have been shown to have important effects on post-MI
cardiac remodelling. It has been known for some time that
superoxide production within certain nuclei of the brain
(including the paraventricular nucleus) is implicated in
mediating the sympathetic activation that occurs after MI
and which predisposes to heart failure [73, 79]. Injection
into the cerebral ventricles of superoxide dismutase (in a
viral carrier) led to reduced activation of neurons in these
CNS nuclei after MI [79], and resulted in reduced apoptosis
and improved cardiac function and survival post-MI [80].
Recent studies showed that NOX4 was the most highly
expressed NOX isoform within the paraventricular nucleus
(PVN) after experimental murine MI and that siRNA-
mediated knockdown of this isoform in the PVN reduced
sympathetic outﬂow from the brain, reduced peri-infarct
apoptosis and improved cardiac performance [54].
The main adverse clinical consequence of cardiac
remodelling is the development of overt heart failure.
Clinical data are available regarding NADPH oxidases in
end-stage heart failure, mostly derived from explanted
failing hearts at the time of transplantation. Our group
demonstrated that NADPH oxidase activity was signiﬁ-
cantly upregulated in such hearts compared to non-failing
hearts and that this was associated with a greater membrane
translocation of p47
phox [49]. Similar ﬁndings were made
by Maack and colleagues [82], who also described
increased Rac1 translocation from cytosol to membrane,
associated with elevated rac1-GTPase activity. Down-
stream pathways have also been examined in this context
and there is evidence of increased activation of ERK1/2
and p38MAPK in parallel with increased NOX activity in
end-stage failing hearts, both in the left and right ventricles
[91]. It has been suggested that the right ventricle may be
more susceptible to increased oxidative stress due to poorer
antioxidant defence activation and that this may be relevant
in the development of overt heart failure [11]. An increase
in NOX2-dependent ROS generation associated with
endothelial dysfunction has also been reported in saphe-
nous veins obtained from patients with heart failure [26],
suggesting that increased NOX2 activation may have wider
systemic effects in the setting of heart failure. In an
experimental model of diastolic heart failure, use of a
pharmacological agent to enhance eNOS activity produced
attenuation of diastolic dysfunction and reduced levels of
NOX2 subunits, suggesting a role for oxidative stress in
modulating cardiac function in this setting too [118].
Conclusions
NADPH oxidases are major sources of ROS in the heart
and vasculature that appear to have an important role in the
pathogenesis of several cardiovascular conditions. While
clinical evidence for their importance is largely correlative,
more robust data derive from experiments in gene-modiﬁed
animals. These studies have largely focused on NOX2 and
NOX1, whereas the roles of NOX4 have been less clear.
Work to date indicates that NOX1 and/or 2-mediated sig-
nalling may be detrimental in hypertension, atherosclero-
sis, cardiac hypertrophy and remodelling. However, recent
work suggests that NOX4 may play a protective role in the
heart subjected to chronic pressure overload as well as in
the vasculature in the setting of hypertension. Additional
research on the isoform-speciﬁc roles of the NOXs and on
the speciﬁc downstream targets that they affect may deﬁne
suitable therapeutic targets for cardiovascular diseases.
Fig. 4 Effect of NOX2 deletion on post-MI remodelling. Represen-
tative M-mode echocardiographic images from NOX2 knockout mice
or wild-type littermates (WT) subjected to left coronary ligation or
sham ligation surgery. The extent of LV dilatation and reduction in
fractional shortening 4 weeks after MI is signiﬁcantly reduced in the
NOX2 knockout group compared to WT. Reproduced with permis-
sion from Looi et al. [81]
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